Literature DB >> 29329721

Quantifying fluctuation in glucose levels to identify early changes in glucose homeostasis in cystic fibrosis.

Rossa Brugha1, Marie Wright2, Suzie Nolan3, Nicola Bridges4, Siobhán B Carr2.   

Abstract

BACKGROUND: Cystic fibrosis related diabetes (CFRD) is associated with increased morbidity in CF. Variability in physiological systems is associated with dysfunctional homeostasis. We examined whether fluctuation in glucose is a marker of CFRD or "pre-diabetes".
METHODS: Using a machine learning approach, we compared glucose IQR to current diagnostic criteria in a review of continuous glucose monitoring data.
RESULTS: Analysis was performed on 248 studies from 142 children. Calculated IQR (cIQR) was increased between children with CFRD, normal glucose homeostasis and indeterminate status (p<0.0001) and impaired glucose tolerance (p<0.05, Kruskal-Wallis test). In subjects who developed CFRD (n=20), cIQR increased between baseline and diagnosis (1.4mmol/L versus 2.4mmol/L, p<0.0001, Wilcoxon test). Area under the curve for CFRD on the basis of cIQR was 0.865 (p<0.0001). Neither episodes of hypoglycaemia nor cIQR at baseline predicted CFRD.
CONCLUSIONS: Glucose fluctuation on CGMS can be quantified by calculating the IQR. This information may improve early recognition of abnormal glucose homeostasis.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Continuous glucose monitoring; Cystic fibrosis; Cystic fibrosis related diabetes

Mesh:

Substances:

Year:  2018        PMID: 29329721     DOI: 10.1016/j.jcf.2017.12.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  1 in total

1.  Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis.

Authors:  Kevin J Scully; Jordan S Sherwood; Kimberly Martin; Melanie Ruazol; Peter Marchetti; Mary Larkin; Hui Zheng; Gregory S Sawicki; Ahmet Uluer; Isabel Neuringer; Lael M Yonker; Leonard Sicilian; Deborah J Wexler; Melissa S Putman
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.